The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease	Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Cerebral Small Vessel Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Fabry disease, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, X-linked disease, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, hereditary disease, inborn errors of metabolism, lysosomal lipid storage disorder, lysosomal storage disease, metabolic disease, nervous system disorder, sphingolipidosis, vascular disorder	Not yet recruiting	Phase 1 / Phase 2	2025-02-11		NCT06819514

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Guangzhou Jiayin Biotech Ltd	6

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Children's Hospital Zhejiang University School of Medicine	Hangzhou	China	7
First Affiliated Hospital of Zhejiang University	Hangzhou	China	7
General Hospital of Eastern Theater Command	Nanjing	China	2